ALL AIDSLINE ASK THE DOC CONFERENCES --5th IAS HIV Pathog & Treat --4th IAS HIV Pathog & Treat --3rd IAS HIV Pathog & Treat --2nd IAS HIV Pathog & Treat --1st IAS HIV Pathog & Treat -Intl AIDS Conferences --17th Int Conf AIDS: Toronto (2006) --16th Int Conf AIDS: Toronto (2006) --15th Int Conf AIDS: Bangkok (2004) --14th Int Conf AIDS: Barcelona (2002) --13th Int Conf AIDS: Durban (2000) --12th Int Conf AIDS: Geneva (1998) --11th Int Conf AIDS: Vancouver --10th Int Conf AIDS: Yokohoma --9th Int Conf AIDS: Berlin --8th Int Conf AIDS: Amsterdam --7th Int Conf AIDS: Florence --6th Int Conf AIDS: San Franciso --5th Int Conf AIDS: Montreal --4th Int Conf AIDS: Stockholm --3rd Int Conf AIDS: Washington --2nd Int Conf AIDS: Paris --1st Int Conf AIDS: Atlanta --9th Intl Cong. Drug Therapy: Glasgow 2008 --8th Intl Cong. Drug Therapy: Glasgow 2006 --7th Intl Cong. Drug Therapy: Glasgow 2004 --6th Intl Cong. Drug Therapy: Glasgow 2002 --5th Intl Cong Drug Therapy: Glasgow 2000 --3rd Intl Cong Drug Therapy: Glasgow 1996 --2nd Intl Cong Drug Therapy: Glasgow 1994 --10th Lipo: London, UK --9th Lipo: Sydney, Australia --8th Lipo: San Francisco --7th Lipo: Dublin, Ireland --6th Lipo: Washington, DC --5th Lipo: Paris, France --4th Lipo: San Diego --3rd Lipo: Athens, Greece --2nd Lipo: Toronto, Canada --1st Lipo: San Diego --15th Conf Retroviruses Opportunistic Infect --14th Conf Retroviruses Opportunistic Infect --13th Conf Retroviruses Opportunistic Infect --12th Conf Retroviruses Opportunistic Infect --11th Conf Retroviruses Opportunistic Infect --10th Conf Retroviruses Opportunistic Infect --9th Conf Retroviruses Opportunistic Infect --8th Conf Retroviruses Opportunistic Infect --7th Conf Retroviruses Opportunistic Infect --6th Conf Retroviruses Opportunistic Infect --5th Conf Retroviruses Opportunistic Infect --4th Conf Retroviruses Opportunistic Infect --3rd Conf Retroviruses Opportunistic Infect --2nd Conf Retroviruses Opportunistic Infect --1st Conf Retroviruses Opportunistic Infect --2005 Natl HIV Prev Conf --2003 Natl HIV Prev Conf --1999 Natl HIV Prev Conf --18th Intl Wkshop HIV Drug Resistance --17th Intl Wkshop HIV Drug Resistance --16th Intl Wkshop HIV Drug Resistance --15th Intl Wkshop HIV Drug Resistance --14th Intl Wkshop HIV Drug Resistance --13th Intl Wkshop HIV Drug Resistance --12th Intl Wkshop HIV Drug Resistance --11th Intl Wkshop HIV Drug Resistance --3rd Intl Wkshop HIV Drug Resistance --5th Intl Wkshop on HIV Drug Resistance & Treatment Strategies --4th Intl Wkshop on HIV Drug Resistance & Treatment Strategies --1st Intl Wkshop on HIV Drug Resistance & Treatment Strategies --15th British HIV Ass'n Conf 2009 --14th British HIV Ass'n Conf 2008 --13th British HIV Ass'n Conf 2007 --12th British HIV Ass'n Conf 2006 --11th British HIV Ass'n Conf 2005 --10th British HIV Ass'n Conf 2004 -- 9th British HIV Ass'n Conf 2003 -- 8th British HIV Ass'n Conf 2002 -- 7th British HIV Ass'n Conf 2001 --9th European AIDS Conf. --8th European AIDS Conf. FACT SHEETS --AIDS Treatment Data Network LAW NEWS SERVICES --AIDS Daily Summary --Agence France-Presse --Asia Times --Associated Press --Bay Area Reporter --BBC On-Line --Bangkok Post --Business Wire --CATIE --Chicago Tribune --FDA News --Inter Press Service --Integrated Regional Information Network --Los Angeles Times --Mail & Guardian --Miami Herald --Newsday --New Vision --New York Times --OC Weekly --PRNewswire --Reuters --San Francisco Chronicle --San Francisco Examiner --Sunday Times --UNAIDS --United Press International --Voice of America --Wall Street Journal --Washington Blade PUBLICATIONS --ACRIA --AIDS Treatment News --AIDS Weekly Plus --amfAR --Being Alive --BETA --BMC AIDS Res Therapy --CATIE --Emerging Infectious Diseases --Gay Men's Health Crisis --HIV Education Project --HIV Treatment Bulletin --IAPAC --IAVI --MMWR --Project Inform PLOS --PLOS Biology --PLOS Medicine --PLOS One --PLOS Pathogens --RITA --Treatment Action Group --Women Alive TOPICS Your Search for active immunity matched 24 Documents (Page 1 of 1). Results Indexed by relevance.
1.	Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain. (70%) Abstract: Using the process of antibody antigenization, we engineered two antibody molecules carrying in the third complementarity-determining region of the heavy chain variable domain a 7-mer or a 15-mer peptide epitope of the first extracellular domain (D1) of human CD4 receptor--namely, Ser-Phe-Leu-Thr-Lys-Gly-Pro-Ser (SFLTK ... http://www.aegis.org/aidsline/1994/mar/m9430295.html File Name: m9430295.html, Size: 11KB, Last Modified: Monday, March 28, 1994 at 8:12:04 PM
2.	Human immunodeficiency virus: an agent that defies vaccination. (35%) Abstract: ... http://www.aegis.org/aidsline/1989/jul/m8970213.html File Name: m8970213.html, Size: 7KB, Last Modified: Wednesday, January 07, 2009 at 5:25:43 AM
3.	AEGiS-NV: Uganda: Country, Sweden Partner to Fight HIV-Related Diarrhoea (35%) Abstract: Kampala - UGANDA and Sweden are conducting a research on diarrhoea associated with HIV/AIDS. The research is aimed at establishing whether ColoPlus, a food supplement, can improve on the immunity of HIV-patients against diarrhoea. This is good news for Uganda s health sector. I am optimistic that the study will be comp ... http://www.aegis.org/news/nv/2008/nv080208.html File Name: nv080208.html, Size: 8KB, Last Modified: Thursday, February 14, 2008 at 3:00:00 PM
4.	AEGiS-15IAC: Pro-Viral HIV-1 DNA PCR test for HIV Diagnosis in Infants. (35%) Abstract: Background;The diagnosis of HIV-1 infection in neonates born to sero positive mothers presents two major dilemmas; the presence of maternal antibodies that preclude the use of serological tests, and the difficulty or impossibility of obtaining large volumes of blood for culture. Objectives;To evaluate a reliable method ... http://www.aegis.org/conferences/iac/2004/b10283.html File Name: b10283.html, Size: 6KB, Last Modified: Monday, July 12, 2004 at 6:29:23 AM
5.	AEGiS-10CROI: The Protective Effect of Passively Transferred Neutralizing Antibody in the Setting of Active Cellular Immunity. (35%) Abstract: <p><b>BACKGROUND:</b> Current HIV vaccine candidates elicit reasonably potent cellular immune responses, but only low levels of neutralizing antibodies. Such CTL based vaccines (e.g., those based on DNA immunization) do not prevent infection, but can have a beneficial effect on disease course. In contrast, passively in ... http://www.aegis.org/conferences/croi/2003/407.html File Name: 407.html, Size: 7KB, Last Modified: Monday, February 10, 2003 at 8:12:04 PM
6.	Immunorestitution disease involving the innate and adaptive response. (35%) Abstract: Immunorestitution disease (IRD) is defined as an acute symptomatic or paradoxical deterioration of a (presumably) preexisting infection that is temporally related to the recovery of the immune system. We report the temporal sequence of events that led to IRD caused by Pneumocystis carinii and Aspergillus terreus in 2 ... http://www.aegis.org/aidsline/2000/nov/a00b0684.html File Name: a00b0684.html, Size: 10KB, Last Modified: Tuesday, November 28, 2000 at 8:12:04 PM
7.	TNF is essential for the cell-mediated protective immunity induced by the radiation-attenuated schistosome vaccine. (35%) Abstract: C57BL/6 mice exposed to the radiation-attenuated schistosome vaccine exhibit high levels of protective immunity. The cell-mediated pulmonary effector mechanism involves IFN-gamma-producing CD4+ T cells in a focal response around challenge larvae. IFN-gamma can promote production of TNF and can synergize with this cyto ... http://www.aegis.org/aidsline/2000/jan/a0010663.html File Name: a0010663.html, Size: 9KB, Last Modified: Friday, January 28, 2000 at 8:12:04 PM
8.	Dendritic cells and immune-based therapies. (35%) Abstract: The dendritic cell (DC) lineage of white blood cells specializes in capturing antigens and stimulating T-dependent immunity. Because of their efficacy in inducing T cell responses in vivo without other adjuvants, DCs can be considered nature s adjuvant. DCs are the least abundant of leukocytes, but methods for generat ... http://www.aegis.org/aidsline/1996/oct/m96a0432.html File Name: m96a0432.html, Size: 9KB, Last Modified: Monday, October 28, 1996 at 8:12:04 PM
9.	Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice. (35%) Abstract: Immunocompetent C.B-17 mice were immunized against Pneumocystis carinii by several intratracheal inoculations with infective P. carinii. These mice and another group of C.B-17 mice naive to P. carinii were then depleted of CD4+ cells by treatment with both anti-CD4 and anti-Thy1 monoclonal antibodies. Both groups of m ... http://www.aegis.org/aidsline/1995/sep/m9590229.html File Name: m9590229.html, Size: 10KB, Last Modified: Thursday, September 28, 1995 at 8:12:04 PM
10.	The diagnosis of toxoplasmosis using IgG avidity. (35%) Abstract: Current methods to establish the duration of toxoplasma infection in pregnant women and for the diagnosis of toxoplasmosis in the neonate or HIV infected patient have significant limitations. We assessed the precision of a commercial ELISA for the detection of toxoplasma specific IgG and adapted the assay to measure a ... http://www.aegis.org/aidsline/1994/jul/m9470569.html File Name: m9470569.html, Size: 10KB, Last Modified: Thursday, July 28, 1994 at 8:12:04 PM
11.	Risk factors for mother-to-child transmission of HIV-1. European Collaborative Study [see comments] (35%) Abstract: Children born to women known to be infected with human immunodeficiency virus type 1 (HIV-1) before delivery were followed prospectively from birth in nineteen European centres. This analysis, encompassing the period end-December, 1984, to beginning-August, 1991, focuses on risk factors for mother-to-child transmissio ... http://www.aegis.org/aidsline/1992/jul/m9270062.html File Name: m9270062.html, Size: 10KB, Last Modified: Tuesday, July 28, 1992 at 8:12:04 PM
12.	Design of conformationally constrained peptide tertiary structural templates (PTST) for AIDS vaccine development. (35%) Abstract: OBJECTIVE: A successful peptide vaccine must overcome several problems that currently exist. Specifically, it must be able to elicit antibodies which can cross-react with the native protein, its antigenic determinants must be the same as the desired viral neutralizing epitopes, and the vaccine must induce active immun ... http://www.aegis.org/aidsline/1991/dec/m91c3610.html File Name: m91c3610.html, Size: 9KB, Last Modified: Saturday, December 28, 1991 at 8:12:04 PM
13.	AEGiS-07IAC: Design of conformationally constrained peptide tertiary structural templates (PTST) for AIDS vaccine development. (35%) Abstract: <p><b>OBJECTIVE</b>: A successful peptide vaccine must overcome several problems that currently exist. Specifically, it must be able to elicit antibodies which can cross-react with the native protein, its antigenic determinants must be the same as the desired viral neutralizing epitopes, and the vaccine must induce a ... http://www.aegis.org/conferences/iac/1991/ma1348.html File Name: ma1348.html, Size: 6KB, Last Modified: Sunday, June 16, 1991 at 8:12:04 PM
14.	Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding. (17%) Abstract: There is evidence that the initial interaction between HIV-1 and the host that is essential for infection is the specific binding of the viral envelope glycoprotein, gp120, to the CD4 molecule found on certain T cells and monocytes. Most individuals infected with HIV develop antibodies against the gp120 protein. Altho ... http://www.aegis.org/aidsline/1989/mar/m8930267.html File Name: m8930267.html, Size: 10KB, Last Modified: Wednesday, January 07, 2009 at 5:27:25 AM
15.	AEGiS-PRn: United Biomedical Inc. Vaccine for HIV (17%) Abstract: SAN FRANCISCO, Feb. 2 /PRNewswire/ -- United Biomedical , Inc. (UBI) of Hauppauge, NY, has developed a synthetic peptide vaccine p2249f. The peptide vaccine evokes potent antibodies effective against a broad range of HIV primary isolates. These are the diverse viruses in worldwide circulation that are responsible for A ... http://www.aegis.org/news/pr/2000/pr000211.html File Name: pr000211.html, Size: 9KB, Last Modified: Wednesday, February 02, 2000 at 3:00:00 PM
16.	AEGiS-PRn: NIAID Public-Private Partnerships Seek to Develop HIV/AIDS Vaccine (11%) Abstract: BETHESDA, Md., June 27 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID) announced today four novel public-private partnerships to accelerate development of promising HIV/AIDS vaccines for use around the world. The new partnerships, called HIV Vaccine Design and Development Teams (HVDDT) ... http://www.aegis.org/news/pr/2000/pr000631.html File Name: pr000631.html, Size: 14KB, Last Modified: Tuesday, June 27, 2000 at 3:00:00 PM
17.	AEGiS-USIS: Text: NIAID Press Release on Partnership to find AIDS Vaccine: $70 million committed to fund public-private joint efforts (8%) Abstract: In order to step up research to develop an effective HIV/AIDS vaccine, the National Institute of Allergy and Infectious Diseases has formed contracts with four private research organizations, NIAID announced in a June 27 press release. ... http://www.aegis.org/news/usis/2000/us000611.html File Name: us000611.html, Size: 14KB, Last Modified: Thursday, February 12, 2004 at 4:47:00 AM
18.	AEGiS-MMWR: Hepatitis A Among Persons with Hemophilia Who Received Clotting Factor Concentrate --- United States, 1995 (5%) Abstract: Hepatitis A Among Persons with Hemophilia Who Received Clotting Factor Concentrate - United States, 1995MORBIDITY AND MORTALITY WEEKLY REPORT, Centers for Disease Control and Prevention January 19, 1996 Vol. 45, No. 2Hepatitis A outbreaks associated with receipt of clotting factor concentrate previously have been re ... http://www.aegis.org/pubs/mmwr/1996/mmwr4502.html File Name: mmwr4502.html, Size: 16KB, Last Modified: Tuesday, August 20, 2002 at 5:17:34 AM
19.	AEGiS-MMWR: Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of Vaccines and Immune Globulins in Persons with Altered Immunocompetence (2%) Abstract: This statement summarizes current recommendations by the Advisory Committee on Immunization Practices (ACIP) on the use of active and passive immunization for persons with altered immunocompetence. The purpose of this statement is to make ACIP recommendations more accessible for clinicians by consolidating them into a ... http://www.aegis.org/pubs/mmwr/1993/rr4204.html File Name: rr4204.html, Size: 48KB, Last Modified: Thursday, February 19, 2004 at 10:42:00 PM
20.	AEGiS-MMWR: Human Rabies Prevention - United States, 1999 Recommendations of the Advisory Committee on Immunization Practices (ACIP) (1%) Abstract: These revised recommendations of the Advisory Committee on Immunization Practices update the previous recommendations on rabies prevention (MMWR 1991;40{No.RR-3}:1-14) to reflect the current status of rabies and antirabies biologics in the United States. This report includes new information about a human rabies vaccine ... http://www.aegis.org/pubs/mmwr/1999/rr4801-1.html File Name: rr4801-1.html, Size: 86KB, Last Modified: Thursday, February 19, 2004 at 10:42:07 PM
21.	AEGiS-MMWR: Guidelines for Prevention of Transmission of Human Immunodeficiency Virus and Hepatitis B Virus to Health-Care and Public-Safety Workers A Response to P.L. 100-607 The Health Omnibus Programs Extension Act of 1988 (1%) Abstract: This document is a response to recently enacted legislation, Public Law 100-607, The Health Omnibus Programs Extension Act of 1988, Title II, Programs with Respect to Acquired Immune Deficiency Syndrome. ... http://www.aegis.org/pubs/mmwr/1989/mm38s06-1.html File Name: mm38s06-1.html, Size: 97KB, Last Modified: Thursday, February 19, 2004 at 10:41:56 PM
22.	AEGiS-MMWR: Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings (0.5%) Abstract: Important note: Information in this article was accurate in January 2003. The state of the art may have changed since the publication date.Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings. MMWR Recommendations and Reports - January 24, 2003 / 52(RR01)1-33 Centers ... http://www.aegis.org/pubs/mmwr/2003/rr5201-1.html File Name: rr5201-1.html, Size: 185KB, Last Modified: Thursday, February 19, 2004 at 10:42:24 PM
23.	AEGiS-MMWR: General Recommendations on Immunization - February 8, 2002 / 51(RR02);1-36 (0.4%) Abstract: This report is a revision of General Recommendations on Immunization and updates the 1994 statement by the Advisory Committee on Immunization Practices (ACIP) (CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices [ACIP]. ... http://www.aegis.org/pubs/mmwr/2002/mm51rr02.html File Name: mm51rr02.html, Size: 225KB, Last Modified: Thursday, February 19, 2004 at 10:42:18 PM
24.	AEGiS-MMWR: Update on Adult Immunization Recommendations of the Immunization Practices Advisory Committee (ACIP) (0.3%) Abstract: This statement on adult immunization is a supplement to the "General Recommendations on Immunization" of the Immunization Practices Advisory Committee (ACIP) (1) and updates the previous supplement published in September 1984. This statement presents an overview on immunization for adults and makes specific immunizatio ... http://www.aegis.org/pubs/mmwr/1991/rr4012-1.html File Name: rr4012-1.html, Size: 322KB, Last Modified: Thursday, February 19, 2004 at 10:41:58 PM
	1
	AEGiS Search Engine. Status: The Index is up to date.